Akebia Therapeutics (AKBA) Free Cash Flow (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Free Cash Flow data on file, last reported at -$21.3 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$21.3 million, down 56.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.0 million (up 272.2% YoY), and the FY2025 annual result was $67.7 million, up 266.37% from the prior year.
• Free Cash Flow retreated to -$21.3 million in Q1 2026 per AKBA's latest filing, from $31.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $33.8 million in Q3 2022 and troughed at -$54.7 million in Q4 2022.
• A 5-year average of -$5.3 million and a median of -$7.2 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 378.18% in 2024, then surged 795.14% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$54.7 million in 2022, then surged by 95.78% to -$2.3 million in 2023, then tumbled by 93.59% to -$4.5 million in 2024, then surged by 795.14% to $31.1 million in 2025, then plunged by 168.48% to -$21.3 million in 2026.
• Business Quant data shows AKBA's Free Cash Flow at -$21.3 million in Q1 2026, $31.1 million in Q4 2025, and $28.0 million in Q3 2025.